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Diagnostic testBackground: Bipolar disorder (BD) is a costly, devastating and life shortening mental disorder that is often
misdiagnosed, especially on initial presentation. Misdiagnosis frequently results in ineffective treatment.
We investigated the utility of a biomarker panel as a diagnostic test for BD.
Methods and findings: We performed a meta-analysis of eight case-control studies to define a diagnostic
biomarker panel for BD. After validating the panel on established BD patients, we applied it to undiag-
nosed BD patients. We analysed 249 BD, 122 pre-diagnostic BD, 75 pre-diagnostic schizophrenia and
90 first onset major depression disorder (MDD) patients and 371 controls. The biomarker panel was iden-
tified using ten-fold cross-validation with lasso regression applied to the 87 analytes available across the
meta-analysis studies.
We identified 20 protein analytes with excellent predictive performance [area under the curve
(AUC)P 0.90]. Importantly, the panel had a good predictive performance (AUC 0.84) to differentiate
12 misdiagnosed BD patients from 90 first onset MDD patients, and a fair to good predictive performance
(AUC 0.79) to differentiate between 110 pre-diagnostic BD patients and 184 controls. We also demon-
strated the disease specificity of the panel.
Conclusions: An early and accurate diagnosis has the potential to delay or even prevent the onset of BD.
This study demonstrates the potential utility of a biomarker panel as a diagnostic test for BD.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Bipolar disorder (BD) is a devastating mental disorder charac-
terised by remitting and relapsing episodes of depression and
(hypo)mania, which can also include psychotic symptoms. Disease
onset commonly occurs in late adolescence or early adulthood,
affecting men and women equally. BD has a lifetime prevalence
of 1.0% for bipolar I disorder and 1.1% for bipolar II disorder
(Merikangas et al., 2007).Diagnosis of BD is based upon operationalized criteria with the
aim to identify BDmood symptoms and patterns. The initial presen-
tation of BD overlaps with either the depressive features of major
depressive disorder (MDD) or the manic psychotic features of
schizophrenia (SCZ). As most individuals seek psychiatric treatment
for depressive symptoms at the onset of the disorder, the condition
is frequently misdiagnosed because the subsequent (hypo)manic
episode cannot be anticipated (Colom et al., 2006; Vieta et al.,
2009). Ghaemi et al. estimated that the average delay for BD
patients to be correctly diagnosed was 7.5 years (Ghaemi et al.,
1999). An MDDmisdiagnosis of BD patients is commonly associated
with inappropriate antidepressant treatment that can precipitate
(hypo)manic symptoms, worsening the outcome for the BD patient.
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genetic risk factors, has not resulted in a diagnostic test for routine
clinical use. However, gene expression studies in monocytes from
BD patients have identified 22 discriminating inflammatory genes
in a whole genome analysis (Padmos et al., 2008). In addition, a
proof of concept whole-genome gene expression study demon-
strated the value of blood biomarkers for predicting BD disease
state (Le-Niculescu et al., 2009). The most promising finding comes
from a case–control study with ‘never-medicated’ BD patients,
where a 10-gene model predicted the patient group with 89%
sensitivity and 75% specificity (p < 0.001) (Clelland et al., 2013).
In this study, we adopted a proteomics based approach to evaluate
the potential of a diagnostic biomarker blood test for BD. After
defining the biomarker panel and the validation in established
BD patients, we applied the test to pre-diagnostic BD patients
and controls, as well as first onset MDD patients, including patients
who later developed (hypo)manic symptoms. We also tested the
specificity of the panel.2. Methods
This study consists of discovery, validation and application stages.
In the discovery stage, we defined a mood-state-independent diag-
nostic biomarker panel for BD in a meta-analysis of eight indepen-
dent case–control studies from five different clinical centres. The
eight studies include a total of 158 established BD patients and
143 controls. In the validation stage, we attempted to validate
the predictive performance of the diagnostic biomarker panel in
a case–control study consisting of a further 66 established BD
patients and 44 controls. Finally, in the application stage, we
applied and evaluated the predictive performance of the diagnostic
biomarker panel in undiagnosed BD patients and tested the disease
specificity of the panel.2.1. Study participants
2.1.1. Discovery stage
Patients were recruited in four clinical centres in Germany
(Cologne, Magdeburg, Münster and Würzburg) and one in the
Netherlands (Rotterdam). The recruitment inclusion and exclusion
criteria were similar for all eight case–control studies. The criteria
required male and female participants to be within the age range of
18–60 years, have a body mass index (BMI) between 18 and 40 kg/
m (Colom et al., 2006), and test negative for recreational drug
screening at the time of sampling (Table 1). BD was diagnosed
according to criteria of the International Classification of Diseases
– 10 (ICD-10) by a trained psychiatrist in a clinical setting. Severity
of symptoms was assessed using standard questionnaire based
rating scales [Hamilton Depression Rating Scale (HAMD), Young
Mania Rating Scale (YMRS) and Montgomery–Åsberg Depression
Rating Scale (MADRS)]. At the clinical centre in Würzburg, BD
(Table 1) was diagnosed by two trained psychiatrists and the
diagnosis was confirmed by the Operational Criteria Checklist for
Affective and Psychotic Illness (OPCRIT). In all clinical centres, both
bipolar I and bipolar II disorder patients were recruited. The BD
patients were in one of the following mood states at the time of
sample collection: depressed, mixed affective, hypomanic, manic
or euthymic (Table 1). Age and sex matched controls from similar
geographical areas, with a similar socioeconomic background were
recruited with a maximum delay of four weeks. The exclusion cri-
teria included a record of mental illness (only applied to controls),
diagnosis of coronary heart disease or cardiac insufficiency,
autoimmune disorders, acute or chronic infections or treatment
with immunosuppressive or immunomodulating drugs or antibi-
otics, other neuropsychiatric disorders or chronic terminal diseasesaffecting the brain, like cancer or hepatic and renal insufficiency,
alcohol or drug addiction. No clinical assessment of controls
was conducted. Patients and controls were fasting for at least
two hours prior to blood sample collection. The study procedures
and protocols received approval from the respective local ethical
committees and informed written consent was obtained from all
participants.2.1.2. Validation stage
We tested the predictive performance of the diagnostic biomar-
ker panel identified in the discovery stage in a further case–control
study from Würzburg in Germany (Table 1). Clinical assessments,
exclusion and inclusion criteria were as described for the discovery
studies.2.1.3. Application stage
We evaluated the predictive performance of the diagnostic bio-
marker panel in three nested case–control studies, two from the US
Department of Defense Serum Repository (DoDSR) and one from
the Netherlands Study of Depression and Anxiety (NESDA). For
the two nested case–control studies from the military, sera were
obtained from the US Department of Defense Serum Repository
(DoDSR), which contains over 55 million serum specimens remain-
ing frommandatory HIV test samples of military personnel (Perdue
et al., 2015; Rubertone and Brundage, 2002). Data and sera retrie-
val were performed by the Armed Forces Health Surveillance Center
(AFHSC) and coordinated by the Military New-Onset Psychosis
Project (MNOPP) investigators at the Walter Reed Army Institute
of Research (WRAIR) (Niebuhr et al., 2008). The medical and demo-
graphic data were provided by the Defense Medical Surveillance
System (DMSS), AFHSC, United States Department of Defense (US
DoD), Silver Spring, Maryland (data range from 1989 to 2006;
released in 2007 and 2008) and serum specimens were retrieved
from the DoDSR, AFHSC, US DoD (Silver Spring, MD, USA; speci-
mens range from 1988 to 2006, released in 2007 and 2008). Sera
were then transferred to the Johns Hopkins School of Medicine
(Baltimore, MD, USA) prior to testing. Samples were then selected
from 185 individuals who presented with psychiatric symptoms
within 30 days after the blood collection and who later received
a DSM-IV diagnosis of either BD or SCZ (MNOPP). Control subjects
were selected from the DMSS records of active duty military ser-
vice population with no inpatient or outpatient psychiatric disor-
der diagnoses. All data were previously collected for other
purposes, and analyses were conducted on de-identified data. As
only de-identified data were utilised, informed consent waivers
were granted by the WRAIR Institutional Review Board (for addi-
tional information please see Supplementary Material 1). The third
nested case–control study was drawn from NESDA, which is an on-
going longitudinal cohort study including 2,981 participants aged
18 through to 65 years (Penninx et al., 2008). Patients from the
NESDA were recruited from three clinical sites in the Netherlands
(Amsterdam, Groningen and Leiden) (Penninx et al., 2008).
A four-hour baseline assessment included written questionnaires,
interviews, a medical examination, a cognitive computer task and
collection of blood and saliva samples. Furthermore extensive
information about key (mental) health outcomes was gathered.
Serum from a subset of 1701 participants was profiled. We anal-
ysed 368 controls and 102 recent onset MDD patients, 12 of which
were diagnosed with BD within two years of the baseline interview
(Table 1).
Informed and written consent was given by all participants, and
the study protocols, analysis of samples and test methods were
approved by the local Institutional Ethics Review Boards and were
in compliance with the Standards for Reporting of Diagnostic
Accuracy.
Table 1
Summary of demographic characteristics of the eight case–control studies used in the meta-analysis (discovery stage), the validation stage and the application stage. Analyte data was acquired between August 2005 and December 2013
(7 years and 4 months). BD – bipolar patients, Controls – control subjects, NR – Not recorded, NA – information not available / not applicable, *missing data points, **cannabis in the past month, d – depressive, e – euthymic, m – manic.
Cohort Rotterdam Würzburg Magdeburg Cologne Münster
Study 1 2 3 4 5 6 7 8
Group Controls BD Controls BD Controls BD Controls BD Controls BD Controls BD Controls BD Controls BD
Discovery
stage
Sample size 40 10 13 28 6 15 18 60 15 7 13 5 12 15 26 18
Age [SD] 26.8
[4.1]
28.3
[11.1]
42.6
[12.3]
47.3
[12.8]
44,5
[15.9]
46,4
[13.5]
45,7
[10.4]
47 [10.9] 40,8
[7.7]
40,4
[7.7]
29,2
[5.8]
28,8
[6.0]
41,7
[7.6]
44,1
[11.1]
44,6
[9.5]
47,3
[14.2]
Sex (m/f) 33/7 7/3 6/7 11/17 3/3 6/7 7/11 29/31 5/10 2/5 8/5 3/2 6/6 5/10 10/16 10//8
BD subtype (1/2) / NR / 15/13 / 5/10 / 30/30 / NR / NR / NA / NR
Mood state (d/e/m/
mixed/NO)
/ NR / 19/0/4/
5/0
/ 1/3/6/5/
0
/ 27/31/1/
1/0
/ NR / NR / NA / NR
Somatic medication NA NA 5/13 14/28 0/6 11/15 4/18 37/60 NR NR NR NR 4/12 2/15 NR
Psychiatric medication 0/40 6/10 0/13 28/28 0/6 15/15 0/18 57/60 0/15 0/7 0/13 NR 0/12 15/15 0/26 NR
Mood stabilizer 0/40 NA 0/13 11/28 0/6 7/15 0/18 55/60 0/15 0/7 0/13 NR 0/12 8/15 0/26 NR
Anti-depressant 0/40 NA 0/13 16/28 0/6 2/15 0/18 37/60 0/15 0/7 0/13 NR 0/12 3/15 0/26 NR
Antipsychiotic 0/40 6/10 0/13 24/28 0/6 8/15 0/18 16/60 0/15 0/7 0/13 NR 0/12 2/15 0/26 NR
BMI [SD] NA NA 26.0
[4.7]⁄
27.5
[6.4]⁄
NA NA 23.6
[3.2]⁄
27.8
[5.5]⁄
25.5
[3.7]
26.8
[7.2]
23.3
[2.1]
23.1
[3.3]
NA NA NR NR
Smoker 10/40 10/10 4/13 11/28 1/6 4/15 2/18 21/60 9/15 5/7 3/13 1/5 2/15 11/15 NR NR
Canabis life time NA 6/10 NA NA NA NA NA NA 1/15 1/7 0/13 0/5 1/12 2/15 NR NR
Molecular profiling May 2009 Nov. 2010 Aug. 2011 Jun 2012 Sep. 2010 Mar 2011 Mar. 2011 Mar. 2011
Study Würzburg Study NESDA USA Military
Disease group Controls BD Disease group Controls First depressive episode patients Controls Pre-diagnostic
First-onset MDD Un-diagnosed BD BD SCZ
Validation stage Sample size 44 66 Application stage Sample size 368 90 12 184 110 75
Age [SD] 29.2 [8.9] 41.9 [13.4] Age [SD] 39.6 [14.9] 38.5 [13.4] 35.4 [10.2] 22.4 [3.6] 21.3 [4.2] 24.3 [4.5]
Sex (m/f) 23/20 24/39 Sex (m/f) 148/220 33/57 5/7 136/48 70/40 67/8
BD subtype (1/2/other) / 35/23/8 BD subtype (1/2) / / / / / /
Mood state (d/e/m/mixed/other) / 28/8/13/13/4 Mood state (d/e/m/mixed) / 90/0/0/0/0 12/0/0/0/0 / / /
Somatic medication 11/44 22/66 0/368 22/90 2/12 NR NR NR
Psychiatric medication 0/44 45/66 0/368 39/90 2/12 0/184 0/110 0/75
Mood stabilizer 0/44 41/66 0/368 0/90 0/12 0/184 0/110 0/75
Anti-depressant 0/44 16/66 0/368 39/90 2/12 0/184 0/110 0/75
Antipsychiotic 0/44 23/66 0/368 39/90 0/12 0/184 0/110 0/75
BMI [SD] 23.8 [4.1]⁄ 27.6 [5.1]⁄ 24.9 [4.6] 25.6 [4.8] 24.7 [2.7] NR NR NR
Smoker 10/44 23/66 96/368 31/90 8/12 NR NR NR
Canabis life time NA NA 21/368 3/90⁄⁄ 1/12⁄⁄ NR NR NR
Molecular profiling Dec. 2013 Apr. 2013 Jun. 2009
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Strict standard operating protocols were adhered to for serum
sample preparation and used by all clinical centres, except for
the U.S. Military (Perdue et al., 2015; Rubertone and Brundage,
2002) and NESDA (Penninx et al., 2008) who have established their
own protocols. The protocol in brief: a blood sample was taken
within two days of the clinical assessment. Serum was collected
from acutely ill fasting patients and controls using Vacutainer
(Becton–Dickinson, Franklin Lakes, NJ, USA). Blood clotting time
was two hours at room temperature prior to centrifugation for
15 min at 1.100g (except for studies 1 and 5–8, which employed
centrifugation for 5 min at 4000g; Table 1). Samples were stored
in low binding Eppendorf tubes (Hamburg, Germany) at 80 C. All
sample shipments took place on dry ice.2.3. Multiplex immunoassay analysis
Serum samples were randomized and processed blind to
disease status using the multiplex immunoassay platform at
Myriad Rules Based Medicine (Myriad RBM; Austin, Texas, USA).
The Human DiscoveryMAPTM assay platform was used to measure
different serum concentrations of proteins, peptides and small
molecules (collectively referred to as ‘analytes’) (Bertenshaw
et al., 2008). The clinical centres all provided anonymised patient
data. The number of analytes measured differed between the
studies depending on when the study samples were profiled (total
range: 147 to 257 analytes). The commonly measured analytes are
reported in Supplementary Table 1.2.4. Statistical analysis
We pre-processed the analyte data from each study to exclude
analytes with greater than 20% missing values and sample outliers
were identified using the first two principal components and to
impute missing data (as described previously (Schwarz et al.,
2011a); Supplementary Table 2). We log10-transformed the data
to stabilize the variance.
All statistical analyses were performed in R (R Core Team,
2014). For the eight studies combined in the meta-analysis, we
used ComBat, as implemented in the sva package (Leek et al.,
2012), to adjust for the effects caused by running the study sam-
ples at different times (i.e. to make the subjects within and
between the studies comparable). ComBat is an empirical Bayes
method of adjusting for additive, multiplicative, and exponential
batch effects developed for analysing microarray data (Johnson
et al., 2007). In addition, we used ComBat to adjust the validation
and application studies for batch effects caused by running sam-
ples within a study on different plates. We did not apply ComBat
to the USA Military studies. 115 analytes and two covariates (age
and sex) were common across the studies (Supplementary Table 1).
We excluded a further 28 analytes with significant BD association
heterogeneity across the studies (Supplementary Table 3). The 87
remaining analytes and two covariates form 289 = 6.2  1026 possi-
ble candidate models. We searched the model space using ten-fold
cross-validation with lasso regression as implemented in the R
package glmnet (Friedman et al., 2010). Lasso is a penalised
method for restricting the residual sum of squares (deviance) and
constraining the sum of the absolute values of the coefficients:
P
ijbj 6 t, where t is the ‘tuning’ parameter. As t !1, t has no
effect and the solutions are the least squares estimates for the full
model. For smaller t values, solutions are shrunken versions of the
least squares estimates with many coefficients decreased to the
null value. t was defined using ten-fold cross-validation, as the
value of t minimising the t-penalised residual sum of squares,which is equivalent to maximising the t-penalised log likelihood
(James et al., 2013). Although the coefficient estimates are biased
to be small, a lasso estimator can have smaller error than a stan-
dard maximum likelihood estimator when applied to new data.
As the analytes were selected based on minimising the
t-penalised residual sum of squares, p-values for each of the
selected analytes are not relevant and not reported. We measured
the predictive performance of the diagnostic biomarker panel
using sensitivity and specificity and area under the receiver oper-
ating characteristic (ROC) curves (AUC: 0.9–1 = excellent; 0.8–0.9 =
good; 0.7–0.8 = fair; 0.6–0.7 = poor; 0.5–0.6 = fail). Optimal
trade-offs between sensitivity and specificity were determined by
maximising Youden’s index (J; where J = sensitivity +
specificity  1).
We attempted to validate the diagnostic biomarker panel
(Table 2) in the independent case–control study from Würzburg
(Table 1). We fit a logistic regression model to the Würzburg ana-
lyte data corresponding to the biomarker panel and predicted BD
status. A similar approach was also adopted in the application
stage. To test the predictive performance of the biomarker panel
in first onset MDD and pre-diagnostic patients, we applied a fitted
model derived from a BD patient–control study that was profiled
and pre-processed at the same time as the MDD or SCZ patients.
For example, in the analysis of the USA Military studies, we fitted
the logistic model to the pre-diagnostic BD patient–control data,
and then applied the fitted model to the pre-diagnostic SCZ
patient–control data.3. Results
3.1. Discovery stage
Eighty-seven analytes and two covariates (age and sex) were
available across the eight case–control studies (183 BD patients
and 149 controls) and included in the variable selection analysis
to define the diagnostic biomarker panel. We identified a biomar-
ker panel of 20 analytes with an excellent predictive performance
(AUC = 0.90; Fig. 1A; boxplots of the log10 transformed analyte
levels are provided in Supplementary Figs. 1). When the selected
analytes were grouped into functional pathways, 11 analytes were
found to play a role in the inflammatory cascade (Table 2). The
majority of these analytes (7 out of 11) have a pro-inflammatory
function and the remainder are anti-inflammatory. A second group
of seven analytes can be clustered into lipid transport-related pro-
teins and proteins with metalloendopeptidase activity.
3.2. Validation stage
The diagnostic performance of the biomarker panel was tested
in an independent case–control study (Table 1). Importantly, as
in the meta-analysis, this study consisted of established BD
patients in different mood states. The predictive performance of
the biomarker panel was excellent (AUC = 0.92; Fig. 1A) despite
the panel being limited to 16 of the 20 analytes selected in the dis-
covery stage (Supplementary Table 4). Note that the analyte model
coefficients were estimated based upon the validation study data
and not upon the meta-analysis.
3.3. Application stage
In this stage, we tested the diagnostic performance of the bio-
marker panel on undiagnosed BD patients and tested the disease
specificity of the panel. It is important to note that the patient sam-
ples used in the application stage were collected at an earlier time
point in the disease course compared to the BD patients from the
Table 2
The 20 analytes selected in the discovery stage to form the diagnostic biomarker panel.
Molecular function Analyte Lasso coefficient
Pro-inflammatory CD40 Ligand 0.11
EN-RAGE 0.06
Growth-Regulated alpha protein 1.81
Macrophage Inflammatory Protein-1 beta (MIP-1 beta) 0.35
Receptor for advanced glycosylation end products (RAGE) 0.30
Serum Amyloid P-Component 1.41
Tumour Necrosis Factor Receptor-Like 2 3.43
Anti-inflammatory Carcinoembryonic Antigen (CEA) 0.46
CD5 1.69
Interleukin-1 receptor antagonist 0.36
Interleukin-10 0.78
Lipid transport Apolipoprotein A1 1.35
Apolipoprotein A2 0.37
Lipoprotein (a) 0.20
Metalloendopeptidase activity Angiotensin-Converting Enzyme (ACE) 0.49
Matrix Metalloproteinase-3 1.87
Matrix Metalloproteinase-7 2.50
Matrix Metalloproteinase-9, total 0.33
Cysteine protease inhibitor Cystatin C 0.53
Growth factor Hepatocyte Growth Factor 0.23
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sentations of MDD and BD (Fig. 1; middle section), and the nega-
tive implications of misdiagnosis, the need for a diagnostic test
to distinguish between the two conditions is clear. To this end,
we tested the predictive performance of the panel on 102 first
onset MDD patients including 12 patients who were subsequently
diagnosed with BD selected from NESDA. All of the 12 misdiag-
nosed BD patients experienced a (hypo)manic episode within
two years of the baseline blood sample collection. We obtained a
good predictive performance (AUC = 0.84; Fig. 1B; Supplementary
Table 4). Two of the 20 panel analytes were not available.
As extensive clinical variables were available in NESDA, we
made these additional variables available for selection (Supple-
mentary Table 5). The addition of the Inventory of Depressive
Symptomatology (IDS) score led to an increase in the test
performance to excellent (AUC = 0.90; Supplementary Fig. 2).
Importantly, IDS scores alone only achieved a fair predictive
performance (AUC = 0.78). We note that the Beck Anxiety Inven-
tory (BAI) score led to a similar increase in the predictive perfor-
mance. In addition, to test the differential diagnostic utility of
the biomarker panel, we applied the fitted model from the analysis
of first onset MDD and misdiagnosed BD patients to differentiate
between 90 first onset MDD patients from NESDA, who did not
develop BD, and 368 controls. Importantly, the predictive perfor-
mance of the biomarker panel for first onset MDD patients was
poor (AUC = 0.64; Fig. 1C).
We then tested the predictive performance of the biomarker
panel in pre-diagnostic BD patients (Fig. 1). We applied the diag-
nostic panel to 110 pre-diagnostic BD patients and 184 controls
from the USA Military, where patients presented with initial
psychiatric symptoms within 30 days of the blood test and later
obtained a diagnosis of BD. The predictive performance was fair,
but bordering the AUC threshold for a good predictive performance
(AUC = 0.79; Fig. 1D). One of the 20 analytes forming the biomarker
panel was not available (Supplementary Table 4). As we also had
75 pre-diagnostic SCZ patient samples from the USA Military,
which underwent protein profiling and were pre-processed at
the same time, we tested whether the biomarker panel could dif-
ferentiate between the pre-diagnostic BD and SCZ patient groups.
The predictive performance was excellent (AUC = 0.91; Fig. 1E).
To test the specificity of the biomarker panel, we applied the fitted
model from the analysis of pre-diagnostic BD patients and controls
to differentiate between pre-diagnostic SCZ patients and controls.
Importantly, the predictive performance was almost equivalentto ‘‘tossing a coin” (AUC = 0.52; classification description ‘fail’;
Fig. 1D).4. Discussion
To date, on-going research has not provided the basis for a diag-
nostic test for BD with clinical utility. In the present study, one of
the largest diagnostic biomarker studies for BD, we demonstrated
for the first time the potential of a biomarker panel to provide a
blood-based diagnostic test for BD.
Given the insidious onset and that most BD patients initially
present with depressive symptoms (Colom et al., 2006), the most
appropriate time for a routine diagnostic test for BD will be when
individuals present with a first depressive episode. When we
applied this panel to differentiate between first onset MDD
patients and patients who later develop (hypo)manic symptoms,
we obtained a good predictive performance (AUC = 0.84). In
addition, incorporation of the IDS rating score, resulted in a further
increase in the predictive performance to excellent levels
(AUC = 0.90; Supplementary Fig. 2).
We also tested the biomarker panel in pre-diagnostic BD
patients and controls (AUC = 0.79), and determined the differential
diagnostic utility of the panel by demonstrating that the BD panel
cannot identify patients from other psychiatric disorders when
those are compared to healthy controls. The panel was applied
to first onset MDD patients and controls (AUC = 0.64) and
pre-diagnostic SCZ patients and controls (AUC = 0.52). Further-
more, and as expected, we were able to demonstrate that the
panel could differentiate between pre-diagnostic BD patients and
pre-diagnostic SCZ patients (AUC = 0.91).
Despite the encouraging diagnostic utility of the biomarker
panel in pre-diagnostic BD patients, a routine diagnostic test to
detect pre-diagnostic patients will not be practical as the preva-
lence of individuals at risk to develop BD will be very low amongst
the population tested.
We have also checked for common analytes in published MDD
(Papakostas et al., 2013; Bilello et al., 2015) and SCZ (Schwarz
et al., 2011b; Chan et al., 2015) diagnostic biomarker panels. The
MDD panel from Papakostas et al. describes a set of nine biomark-
ers, of which seven were also measured in the present study
(Supplementary Table 1). None of the seven analytes were
included in the BD panel. A more recent study compared 687
current and 482 remitted MDD patients with 420 controls
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Fig. 1. A summary of the typical disease progression of BD and ROC curves derived from the discovery, validation and application stages. Middle section: Typical course of BD
starting from no overt symptoms, an initial depressive episode and followed by a chronic remitting–relapsing disease course is depicted in blue; the dotted red line depicts a
chronic MDD disease course. Note that a sub-group of BD patients (BD2) only experience (hypo)manic episodes, these patients are not represented in the figure. The labels A,
B and C indicate corresponding disease stages represented in the ROC curves with the same lettering. Top and bottom sections, ROC curves and predictive performance: (A)
The discovery and validation studies – established BD patients and controls; (B) First onset ‘‘MDD patients” including patients who later developed BD (NESDA); (C) First
onset MDD patients and controls (NESDA); (D) Pre-diagnostic BD, pre-diagnostic SCZ and controls (USA military); (E) Pre-diagnostic BD and pre-diagnostic SCZ (USAMilitary).
(For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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ged. Five of the analytes are also present on the BD biomarker
panel (carcinoembryonic antigen, EN-RAGE, growth-regulated
alpha protein, interleukin-1 receptor antagonist and matrix
metalloproteinase-3) (Romi et al., 2012). The study tested 171 ana-
lytes for significance of which 101 are in common with the 115
analytes available in the discovery phase of this study.
When compared to the diagnostic SCZ biomarker panel
reported by Schwarz et al., we found three overlapping biomarkers
(cluster of differentiation 40, interleukin-10 and carcinoembryonic
antigen) of the described 34 biomarkers (19 analytes measured in
common) (Schwarz et al., 2011b). The second, more comprehen-
sive, SCZ panel, published by Chan et al., describes a 26 analyte
panel and used a similar statistical approach to the one in this arti-
cle. Out of 60 commonly measured analytes, three analytes are in
common with the BD panel (apolipoprotein A1, interleukin-10
and interleukin 1 receptor antagonist) (Chan et al., 2015).
The molecular mechanisms of the selected analytes, which can
distinguish BD patients in different disease stages (pre-diagnostic,
first depressive episode and established patients), potentially
reveal new insights into the progressive nature of BD.
Importantly, three analytes (Matrix-metalloproeinase-3 (MMP-
3), MMP-7 and MMP-9) belong to a structurally related family of
secreted proteases that play an important role in extracellular
matrix degradation (Chopra et al., 2014). Matrix-metalloproteinases
(MMPs) have been implicated in the regulation of cell survival,
angiogenesis, cell signalling and the maintenance of an intact
blood–brain barrier. Alterations in serum levels of several MMPs
have been reported for neurodegenerative and neuroinflammatory
diseases like Alzheimer’s disease and multiple sclerosis (MS) (Romi
et al., 2012; Waubant et al., 1999).
Overexpression of MMPs, including MMPs secreted by T-cells
and macrophages, are known to damage and open the blood brain
barrier (Chopra et al., 2014; Leppert et al., 1995; Rosenberg et al.,
1992). MMP-3, -7 and -9 expression is increased in astrocytes,
microglia and neurons surrounding white matter lesions in MS
(Cossins et al., 1997; Maeda and Sobel, 1996). MMP-9 expression
levels in brain tissue of MS patients were reported to be correlated
with increased serum levels (Waubant et al., 1999). We found
increased levels of MMP-9 and -7 in serum from BD patients, while
MMP-3 levels were decreased. Interestingly, MS patients have a
significantly higher life-time risk to develop BD (Carta et al.,
2014). In addition to MMPs, antipsychotic treatment might further
contribute to blood–brain barrier dysfunction (Zetterberg et al.,
2014).
Over half of the analytes (11/20) in the panel were associated
with inflammatory processes. Seven of these analytes are pro-
inflammatory mediators and the remaining four are anti-
inflammatory (see Table 2). Levels of three of the seven pro-
inflammatory analytes (CD40 Ligand, Growth-Regulated alpha pro-
tein and Receptor for advanced glycosylation end products) were
decreased and in addition, three anti-inflammatory analytes (Car-
cinoembryonic Antigen, Interleukin-1 receptor antagonist and
Interleukin-10) were found to be increased in BD patients. These
findings do not support some published results, which report a
predominant increase of pro-inflammatory analytes in BD
(Barbosa et al., 2014; Rosenblat and McIntyre, 2015; Kupka et al.,
2002; O’Brien et al., 2006). However, a few studies support our
findings of an imbalance in pro-inflammatory and anti-
inflammatory mediators in BD (Kim et al., 2007; Knijff et al.,
2007). In addition, a recent study also reported elevated levels of
carcinoembryonic antigen (CEA) in BD patients (Kaplan et al.,
2015). CEA is involved in the activation and production of anti-
inflammatory cytokines such as IL-10 (Thomas et al., 2011). The
authors suggest that CEA could have utility for diagnosing BP
(Kaplan et al., 2015).A third functional group of changing serum proteins in BD relate
to decreased levels of Apolipoprotein A1 and A2 and increased
levels of Lipoprotein (a), which facilitate cholesterol and triglyc-
eride transport, but also play a role in regulation of inflammation
(Keeney et al., 2013). Decreased levels of Apolipoprotein A1 have
been found in serum and cerebrospinal fluid of patients suffering
from a wide range of neurodegenerative disorders (Keeney et al.,
2013). These findings are also consistent with an increased risk
for cardiovascular events in BD, which support the understanding
that BD, like many other chronic disorders such as diabetes, cardio-
vascular disease and neurodegenerative disorders, presents with
prominent immune alterations. Interestingly, the immune changes
that we identified for bipolar disorder appear to be distinct from
those seen in schizophrenia and major depressive disorder
(Papakostas et al., 2013; Chan et al., 2015; Lakka et al., 2002).
The ideal study to distinguish biomarkers which are either
cause or effect of a BD disease process, would be to conduct a
prospective study to monitor the levels of the various analytes in
the same probands/patients over time and to relate these analytes
with clinical symptomology and treatment. However, this would
be a substantial undertaking and unfortunately this question can’t
be addressed in the present study. The key goal of our study was to
try to evaluate the utility of a biomarker panel for the diagnosis of
bipolar disorder.
However, the fact that the same protein signature can identify
individuals who have (as yet) not developed overt symptoms and
were diagnosed with bipolar disorder (military cohort; NESDA
misdiagnosed group) provides at least some evidence that the
identified changes are not secondary to disease state or medication
and may be aetiologically linked to the disorder (see Supplemen-
tary Table 6 for a representative overview of BD patient medica-
tion). However, it remains unclear whether the identified
alterations are secondary to developmental, environmental and/
or genetic factors. Unfortunately, this is also the case for other
chronic, late onset disorders such as cardiovascular disease,
diabetes and many others.
Nevertheless, it is possible that the inflammatory dysregulation
is precipitating the onset of psychopathology and therefore may
represent a therapeutic target (Chan et al., 2014). Ayorech et al.
have reviewed sixteen studies using off target anti-inflammatory
medication and conclude that there is indeed evidence for efficacy
of anti-inflammatory medications in BD treatment (Ayorech et al.,
2014).
There are several limitations to the present study. Firstly, we
did not take different bipolar sub-classifications (i.e. BP1 versus
BD2) and mood states at the time of sample collection into
account. Secondly, we cannot rule out that a small number of the
biomarkers in the panel may be associated with medication
rather than disease status. However, we have demonstrated that
medication as cofounding factor is very unlikely to have a strong
impact on the biomarker panel. If the biomarker panel was
discriminating between bipolar patients and controls primarily
based on medication, we would expect this panel to have a limited
predictive performance in the antipsychotic naïve pre-diagnostic
(Supplementary Material 1) and ‘misdiagnosed’ (NESDA; only
2 of 12 patients were on antidepressant medication and none
received mood stabilising or antipsychotic medication) bipolar dis-
order patient cohorts. In contrast, we see a fair to good predictive
performance.
A second general limitation of this study is the lack of consistent
demographic data across all clinical centres. As age and sex were
the only covariates available across the eight case–control studies
used in the meta-analysis, we identified a diagnostic test without
considering other relevant clinical variables, like symptom scores.
Of all the studies analysed, the most relevant for a diagnostic test
was the nested study from NESDA. However, only a small number
56 F. Haenisch et al. / Brain, Behavior, and Immunity 52 (2016) 49–57of BD patients who were initially diagnosed with MDD and later
developed BD symptomatology were available, larger studies will
be necessary to validate the findings from NESDA.
In conclusion, the 20 analytes reported here, represent a prelim-
inary panel of validated biomarkers from which a definitive signa-
ture for the diagnosis of BD could be developed. The ultimate goal
will be to implement a low-cost blood test that can be routinely
used in primary and secondary clinical care settings in conjunction
with a clinical interview for the diagnosis of BD before the develop-
ment of hypomanic or manic symptoms.
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